The present study strongly suggests that rituximab, a monoclonal antibody against CD20 on B cells, does not permanently deplete pathogenic B cell responses against Dsg3 in patients with PV, a potentially lethal autoimmune bullous disorder of skin and mucosa. This evidence concerns the gene DSG3 and acquired polycythemia vera.